15 citations
,
April 2011 in “The journal of investigative dermatology/Journal of investigative dermatology” A3B5 can reduce skin pigmentation and slow melanoma growth.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
4 citations
,
September 2025 in “Journal of the American Academy of Dermatology” January 2026 in “Journal of Investigative Dermatology” 3D imaging effectively tracks skin changes in vitiligo treatment.
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.
March 2026 in “Preprints.org” Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
2 citations
,
March 2023 in “Frontiers in medicine” A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Rituximab can cause skin issues, but baricitinib may help improve them.
2 citations
,
May 2023 in “Journal of Immunotherapy” Sintilimab treatment caused hair loss but led to complete tumor remission.
2 citations
,
October 2018 in “Archives of Dermatological Research” Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.
Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.
September 2023 in “Journal of the American Academy of Dermatology” Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
1 citations
,
January 2020 in “Surgical & Cosmetic Dermatology” Combining oral minoxidil with JAK inhibitors helps regrow hair in severe alopecia areata cases.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.
September 2025 in “Arthritis Research & Therapy” BMS-470539 reduces skin fibrosis and inflammation.
12 citations
,
November 2017 in “European Annals of Allergy and Clinical Immunology” Omalizumab can cause temporary hair loss but still works well for chronic urticaria.
June 2025 in “BMJ Case Reports” Axitinib treatment turned a man's grey hair back to black.
4 citations
,
January 2014 in “The Journal of urology/The journal of urology” Kidney cancer cells without folliculin are more sensitive to radiation due to increased self-eating cell death.
July 2025 in “Journal of Investigative Dermatology” Upadacitinib effectively treats pyoderma gangrenosum.
April 2024 in “Clinical and experimental dermatology” Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.
Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.
April 2026 in “Frontiers in Medicine” Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.
86 citations
,
June 2018 in “Cochrane library” Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.
18 citations
,
May 2013 in “Cutaneous and Ocular Toxicology” The cancer drugs bortezomib and lenalidomide cause skin side effects in many patients.
3 citations
,
February 2023 in “BMJ Case Reports” OnabotulinumtoxinA treatment improved hair-pulling disorder and hair regrowth in a woman with chronic migraines.
2 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
October 2022 in “Amplla Editora eBooks” Tocilizumab might be an effective treatment for COVID-19.
32 citations
,
June 2012 in “PLoS ONE” Blocking IL-8 can reduce skin rashes from cancer treatment.
April 2024 in “JEADV clinical practice” Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.